MCL
For many, the path to a correct diagnosis can be long and filled with uncertainty. This story highlights the resilience and determination of one patient who navigated a complex medical journey to find answers and hope at Mayo Clinic. The patient asked to remain anonymous for personal privacy reasons.
In this microlearning, you'll learn about the essential components of an effective leadership onboarding program. You'll also discover common challenges new leaders face and how a well-structured onboarding process can support them in overcoming these obstacles.
On this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., speaks with Erinn Downs, D.O., professor of laboratory medicine and pathology at Mayo Clinic’s Arizona campus, on the topic of benign mimics of malignant breast pathology.
PACE/State of FL - How artificial intelligence and digital pathology have the potential to revolutionize the clinical laboratory landscape.
The following cases are designed for healthcare professionals interested in understanding the assessment and treatment options for patients with systemic lupus erythematosus disease.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test.
In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.
Medical Laboratory Professionals Week is a time to appreciate the profound impact of laboratory medicine on healthcare and innovation.
Communication is a critical component of success. Laboratory outreach leaders can foster truly effective communication with five simple steps.
Learn why threshold diagnoses of the breast are important, how to approach them, and what role technology might play in the future.
Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.
By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial therapies.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT).